NYSE •
Healthcare •
Biotechnology •
Quote as of 06/15/2026 15:10
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization316.61 mln
Float187 mln
Earnings Date08/06/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-0.32
Highly suspicious
Relative Strength
25
/ 100
Underperforming
Debt / Equity
0.04
Debt-free
ROE
-130
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Lineage Cell Therapeutics is a California-based biotechnology company focused on developing therapies that replace damaged or lost cells to treat serious conditions affecting vision, hearing, the nervous system, and metabolism. Its most advanced programs include a retinal cell therapy for age-related macular degeneration and a nerve cell therapy for spinal cord injuries, both currently in clinical trials. The company also has several earlier-stage programs in development, targeting conditions such as hearing loss, diabetes, and photoreceptor damage, and works with outside partners to advance some of these efforts. Formerly known as BioTime Inc., the company has been operating since 1990.